By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Biogen Idec, Inc. (Massachusetts) 

225 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 781-464-2000 Fax: n/a


Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit




CEO: George A. Scangos, PhD

CMO: Alfred W. Sandrock, Jr., M.D., PhD

CFO: Paul J. Clancy


Please click here for Biogen job opportunities..


Please click here for clinical trial information.


Please click here for product information..


Key Statistics

Ownership: Public

Web Site: Biogen
Employees: 1700
Symbol: BIIB



NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan  (crohn's & MS)

Dyax  Antibody phage display



Dow AgroSciences LLC 


Company News
Biogen (BIIB)’s IMRALDI, An Adalimumab Biosimilar Candidate Referencing Humira, Granted Positive Opinion By Committee For Medicinal Products For Human Use 6/23/2017 7:13:38 AM
Biogen (BIIB) To Report Second Quarter 2017 Financial Results And Strategic Update On July 25, 2017 6/21/2017 6:54:52 AM
Alzheimer's Drug Leads UBS To Upgrade Biogen (BIIB) 6/21/2017 6:50:47 AM
Biogen (BIIB) Brings Ex-Shire (SHPG) Exec Into C-Suite 6/20/2017 5:57:34 AM
Life Sciences Professionals Name Top 30 Ideal Employers 6/15/2017 10:43:10 AM
Real World Data Being Presented At EULAR 2017 Demonstrate Acceptance And Confirm Sustainability Of Effectiveness, Safety And Adherence Among Patients Switching To BENEPALI (Etanercept Biosimilar Of Biogen (BIIB) From Reference Etanercept 6/15/2017 7:39:39 AM
What Biogen (BIIB) CFO's Departure Means for Company's M&A Strategy 6/15/2017 5:59:49 AM
Real World Data Being Presented At EULAR 2017 Demonstrate Acceptance And Confirm Sustainability Of Effectiveness, Safety And Adherence Among Patients Switching To BENEPALI® (Etanercept Biosimilar Of Biogen (BIIB)) From Reference Etanercept 6/14/2017 8:25:59 AM
Biogen (BIIB) Release: Jean-Paul Kress Appointed EVP And President, International And Head Of Global Therapeutic Operations 6/14/2017 6:44:30 AM
Accenture And 1QBit Work With Biogen (BIIB) To Apply Quantum Computing To Accelerate Drug Discovery 6/14/2017 6:41:01 AM